BioSpec Global Solutions Inc., announced today that it has entered into formal talks with Canadian representative for a major Chinese distributor

NEW YORK and MONTREAL, Nov. 17 /PRNewswire-FirstCall/ - BioSpec Global Solutions Inc., and partner -ICBS Ltd. (OTCPK: ICBT), announced today that the company has entered into talks with a Canadian representative of a major Chinese distribution company. "China is one of the world's largest markets for our analyzer's and has one of the worst water situations on the planet" said Don Saunders President and CEO of BioSpec Global Solutions. We hope to complete a deal with the Chinese the next 60 days."The company is gearing up for production of the TOG's 3000 which will lead the market development in China. BioSpec Global Solutions, has developed the TOGS 3000 to analyze total bacterial count in water samples. Given the advantages not only on time advantage ( 24 Hours for test results) but the accuracy of these machines, can equip agencies with the technology needed to insure safe drinking water for their citizens.Verification studies for the TOGS(TM) 9000 has been completed by Ryerson University and the instrument has, like the Pro3000(TM), been accepted by the EPA in the USA for use in presence absence testing of drinking water when used with an EPA approved method and reagent. The TOGS(TM)9000 has been used by the United Nation for a emergency relief project in the Dominican Republic. A verification study by Michigan State University, an EPA laboratory, is ongoing for viruses. Further verification and validation studies will be done shortly by users and ETV (Environmental Technology Verification) for microbial quantification for beach and wastewater applications.The company holds worldwide patents on the TOGS 3000 and 9000.NB. This news release includes statements that constitute forward-looking statements. Please be aware that any such forward-looking statements are not guarantees of future performance and involve significant ...
Click here to read the whole Article (external link)

BioSpec Global Solutions Inc., to target major food manufacturing companies, to eradicate the possibility of undetected E.coli contamination of fresh produce

NEW YORK and MONTREAL, Nov. 13 /PRNewswire-FirstCall/ - BioSpec Global Solutions Inc., and partner -ICBS Ltd. (OTCPK: ICBT), announced today that the company will be targeting major food producers in the U.S. and Canada for the use of the TOG'S 9000(TM) which has proceeded in the development of Antibody/antigen multiple discrete optical system (AMUDOS) for the simultaneous analysis of E.coli, in fresh produce. "We have seen the disastrous results of food contamination by E.coli in fresh vegetables and packaged salads in the past" said Don Saunders President and CEO of BioSpec Global Solutions Inc., "BioSpec will be targeting the major manufactures and producers in the coming year to introduce the TOG's 9000(TM) system, and Software and methodologies for simultaneous detection and enumeration of the above microbes in various types of food samples. TOGS 9000 new model will be a method for the enumeration of total Coliforms, E.coli and Enterococci in fresh water.""The public have been at risk because of the inability of food companies to have fast reliable detection of the presence of E.coli in foods, BioSpec Global Solutions wants to make this type of instance a thing of the past."The Pro3000(TM) has been verified by Ryerson University, Agriculture Canada and Saskatchewan Department of Health. It has been accepted for use for drinking water analysis by EPA in the USA when used in conjunction with an EPA approved reagent The TOGS 9000 and 3000 have been used in a research project by the World Health Organization in Hawaii and by OCETA in India.The company holds worldwide patents on the TOGS 3000 and 9000.NB. This news release includes statements that constitute forward-looking statements. Please be aware that any such forward-looking statements are not guarantees of future performance and involve significant risks and uncertain...
Click here to read the whole Article (external link)

BioSpec Global Solutions Inc., announces the appointment of Richard Howarth as Technical Director

NEW YORK, NY, and MONTREAL, Nov. 9 /PRNewswire-FirstCall/ - BioSpec Global Solutions Inc., and partner -ICBS Ltd. (OTCPK: ICBT), announced that Richard Howarth has been appointed Technical Director. Mr. Howarth received his B.Sc., in Applied Chemistry of Polymers in 1971 from Manchester, Polytechnic in the UK. He is currently the Senior Technologist at Bombardier Aerospace, and has been with Bombardier for the past 28 years."Mr. Howarth will be involved in all of the new R&D projects for the advanced TOGS(TM) 9000." Said Don Saunders President and CEO BioSpec Global Solutions. "We are very excited about the addition to our team of someone with Mr. Howarth' s experience."The development will include the building of hardware and optical system. Software and methodologies for simultaneous detection and enumeration of the microbes in various types of food samples. TOGS 9000 new model will be a method for the enumeration of total Coliforms, E.coli and Enterococci in fresh water, marine water for routine recreational water testing.The second phase will be the development and site method validation (for FDA approval) of viable microbial count (VMC or total bacterial count) in water for pharmaceutical quality assurance process.Having the ability to test water efficiently and quickly can provide pharmaceutical companies with the ability to monitor their production systems.The Pro3000(TM) has been verified by Ryerson University, Agriculture Canada and Saskatchewan Department of Health. It has been accepted for use for drinking water analysis by EPA in the USA when used in conjunction with an EPA approved reagent The TOGS 9000 and 3000 have been used in a research project by the World Health Organization in Hawaii and by OCETA in India.The company holds worldwide patents on the TOGS 3000 and 9000. NB. This ...
Click here to read the whole Article (external link)

Canadian Bio Med Systems Inc., appoints Dr. George Tsoukas as Medical Director

NEW YORK, NY, MONTREAL, and SAN DIEGO, CA, Nov. 2 /PRNewswire-FirstCall/ - Canadian Bio Med Systems Inc., a subsidiary of ICBS Ltd., (OTCPK: ICBT), and Ocular Therapeutics Inc., of San Diego California, announced today that Dr George Tsoukas, M.D. has agreed to become Medical Director of Canadian Bio Med Systems Inc. Dr. George Tsoukas of Montreal, has been appointed Medical director to oversee the testing and clinical trials for the new drug, LD22-4 which treats Age-Related Macular Degeneration of the eye. Endocrinologist, Associate Professor, McGill University Health Center, Montreal, Quebec, Dr. Tsoukas, a noted physician and educator, is a physician at the McGill University Medical Center in Montreal and has conducted numerous clinical trials.Dr. Tsoukas has extensive experience in medical education and was chief examiner for the Quebec College of Endocrinologists and was an honours student in biochemistry at McGill University. He obtained his medical degree at the same university and received further training in internal medicine, cardiology, and endocrinology. He is a fellow in the Royal College of Physicians and Surgeons of Canada.Age-Related Macular Degeneration (AMD) is the leading cause of blindness, worldwide, for people over 55 years of age. The incidence of AMD in persons aged 55 is 1% and increases to 15% for persons aged 80. This debilitating disease has proven to be difficult to treat and only a very few drugs have been developed which have positive effects.The drug under development by Canadian Bio Med Systems , has a very different mode of action than the current therapeutic products. It can be used alone or in conjunction with these currently available products.The product under development by CBMS, LD22-4 has the advantage of being a very small molecule meaning that fewer treatments will be needed compare...
Click here to read the whole Article (external link)

BioSpec Global Solutions Inc., announced today a new R&D program for the analysis of Antibiotic resistant microbes

NEW YORK and MONTREAL, Oct. 27 /PRNewswire-FirstCall/ - BioSpec Global Solutions Inc., and partner - ICBS Ltd. (OTCPK: ICBT), announced today a new R&D project for a multiple test system for antibiotic resistant Microbes. BioSpec Global Solutions Inc., is to develop a multiple test system for the analysis of Antibiotic Resistant Microbes (ARMs) and Antibiotic Susceptible Microbes (ASMs) in clinical samples. The idea is to develop an apparatus with 6-8 sample tests in a single unit. A sample is divided into 6 (or 8)and are tested simultaneously. In each sample test vessel a specific antibiotic will be added which is generally prescribed by the doctors for suspected bacterial infection. As an average the test can be done in 3-4 hours. This will provide the doctor which antibiotic works for this infection or if the tested patient is carrying an ARM (antibiotic resistant bacteria). If the antibiotic works, that test sample will not show growth of the microbe in question. Putting these in a doctor's office, they can test and make a decision as to how to treat the patient in about 4 hours. Currently, the doctors will have to take a sample and send to a lab and wait for 3-5 days to know what type of microbe they are dealing with. Meanwhile, they may have to prescribe an antibiotic hoping that will work. This new technology prevents prescribing unwanted antibiotic usage which is the root cause of creating these ARM's in the first place.The TOGS 9000 is a bio-photonic incubation/detection instrument which quantifies microbial contamination. The analysis results can be obtained directly on-site through a computer or can be directly connected and controlled by an appropriate laboratory and or regulatory authority in a secure monitoring system using 'AGACSS(TM)' software and the internet.The company holds worldwide patents on the TOGS 3000 and 90...
Click here to read the whole Article (external link)

BioSpec Global Solutions Inc., announced today that it has filed Eurasian patents for market expansion into China

NEW YORK, MONTREAL, Oct. 14 /PRNewswire-FirstCall/ - BioSpec Global Solutions Inc., and partner -ICBS Ltd. (OTCPK: ICBT), announced today the filing of Eurasian patents in anticipation of entry into China. "China is one of the world's largest markets for our analyzer's and has one of the worst water situations on the planet" said Don Saunders President and CEO of BioSpec Global Solutions.The company is currently in talks with an undisclosed Chinese company representative in Canada. BioSpec Global Solutions, has developed the TOGS 9000 to analyze total bacterial count in water samples. Given the advantages not only on time advantage ( 10 Hours for test results) but the accuracy of these machines, can equip agencies with the technology needed to insure safe drinking water for their citizens.Verification studies for the TOGS(TM) 9000 has been completed by Ryerson University and the instrument has, like the Pro3000(TM), been accepted by the EPA in the USA for use in presence absence testing of drinking water when used with an EPA approved method and reagent. The TOGS(TM) 9000 has been used by the United Nation for a emergency relief project in the Dominican Republic. A verification study by Michigan State University, an EPA laboratory, is ongoing for viruses. Further verification and validation studies will be done shortly by users and ETV (Environmental Technology Verification) for microbial quantification for beach and wastewater applications.The company holds worldwide patents on the TOGS 3000 and 9000.NB. This news release includes statements that constitute forward-looking statements. Please be aware that any such forward-looking statements are not guarantees of future performance and involve significant risks and uncertainties, and that actual results may vary materially from those in the forward-looking statements as a re...
Click here to read the whole Article (external link)

Canadian Bio Med Systems Inc., to move AMD project to Canada to take advantage of government funding.

NEW YORK, MONTREAL and SAN DIEGO, Sept. 28 /PRNewswire-FirstCall/ - Canadian Bio Med Systems Inc., a subsidiary of ICBS Ltd., (OTCPK: ICBT),) , and Ocular Therapeutics Inc., of San Diego California, announced today that the company will be moving the AMD project to Canada to take advantage of the R&D funding by both the Canadian and provincial governments. Age-Related Macular Degeneration (AMD) is the leading cause of blindness, worldwide, for people over 55 years of age. This debilitating disease has proven to be difficult to treat and only a very few drugs have been developed which have positive effects.The drug under development by Canadian Bio Med Systems , has a very different mode of action than the current therapeutic products. It can be used alone or in conjunction with these currently available products."We have already demonstrated in several different animal models that angiogenesis is dramatically suppressed in the presence of LD22-4," said Eugene Levin, Ph.D., He added, "The proposed method of administration of LD22-4, intravitreal injection, is commonly used to administer ophthalmic drugs and generally accepted by patients facing the prospect of blindness and other serious back of the eye complications. However we believe that our therapy can be adopted to offer a less invasive method of administration that may have a competitive advantage over one administered by intravitreal injection."LD22-4 is currently in Phase One studies and a patent application has been filed for the therapeutic use of this product.The market for products treating AMD has been estimated at over $2 billion annually and growing at a rate of over 10% yearly as the population ages.The Research & Development tax credit programs in Canada, offer the company the ability to receive back up to 75% of the costs involved with the de...
Click here to read the whole Article (external link)

BioSpec Global Solutions Inc., announces new R D project for testing pharmaceutical grade water used in line testing

NEW YORK, NY, and MONTREAL, Sept. 16 /PRNewswire-FirstCall/ - BioSpec Global Solutions Inc., and partner -ICBS Ltd. (OTCPK: ICBT), announced today a new R D project development of a method for pharmaceutical process water in line testing. Developing methods for TOGS 9000 to analyze total bacterial count in water samples. Application in pharmaceutical process water (in-line production testing). The development include the building of hardware and optical system. Software and methodologies for simultaneous detection and enumeration of Pharmaceutical water used in processing and manufacturing ."Moving forward with this new R D projects will allow the company to develop a wide range of testing procedures for the Pharmaceutical industry." Said Don Saunders President and CEO BioSpec Global Solutions. "Without constant and proper testing there is always a health concern as water, whether it be drinking water or pharmaceutical grade water can become contaminated.Having the ability to test water efficiently and quickly can provide pharmaceutical companies with the ability to monitor their production systems.The Pro3000(TM) has been verified by Ryerson University, Agriculture Canada and Saskatchewan Department of Health. It has been accepted for use for drinking water analysis by EPA in the USA when used in conjunction with an EPA approved reagent The TOGS 9000 and 3000 have been used in a research project by the World Health Organization in Hawaii and by OCETA in India.The company holds worldwide patents on the TOGS 3000 and 9000.NB. This news release includes statements that constitute forward-looking statements. Please be aware that any such forward-looking statements are not guarantees of future performance and involve significant risks and uncertainties, and that actual results may vary materially from those in the forward...
Click here to read the whole Article (external link)

BioSpec Global Solutions Inc announces new project development for the testing method for the enumeration of Coliphage virus in drinking water

NEW YORK and MONTREAL, Sept. 8 /PRNewswire-FirstCall/ - BioSpec Global Solutions Inc., and partner - ICBS Ltd. (OTCPK: ICBT), announced today a new project development of a method for the enumeration of Coliphage virus in drinking water. The development include the building of hardware and optical system. Software and methodologies for simultaneous detection and enumeration of the above virus in drinking water. TOGS 9000 model will be a method for the enumeration of total Coliphage virus in fresh water testing."Moving forward with our new R D projects will allow the company to develop a wide range of testing procedures for the TOGS 9000 units. The TOGS 9000 allows 100% accuracy test results in hours versus days in a conventional laboratory." Said Don Saunders President and CEO BioSpec Global Solutions. "Without constant and proper testing there is always a health concern as water, whether it be drinking water or recreational water can become contaminated quickly with disease following just as fast. The World Health Organization has set standards for these indicator organisms that have been adopted by most countries around the world."Recent studies have shown that the fecal indicator bacteria (FIB) currently used to indicate water quality in the coastal environment may be inadequate to reflect human viral contamination. Coliphage was suggested as a better indicator of human viral pollution and was proposed by the U.S. EPA as an alternative indicator for fecal pollution in groundwater.The Pro3000(TM) has been verified by Ryerson University, Agriculture Canada and Saskatchewan Department of Health. It has been accepted for use for drinking water analysis by EPA in the USA when used in conjunction with an EPA approved reagent The TOGS 9000 and 3000 have been used in a research project by the World Health Organization in Hawaii and by O...
Click here to read the whole Article (external link)

BioSpec Global Solutions Inc announces development of Antibody/antigen multiple discrete optical system for the simultaneous analysis of E.coli, salmonella, listeria and pseudomonas in food samples

Copyright © 2009 Yahoo! All rights reserved. Privacy Policy - Terms of Service - Copyright Policy - Report Problems Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quote data delayed 15 minutes for Nasdaq, NYSE and Amex. Real-Time continuous streaming quotes are available through our premium service. You may turn streaming quotes on or off. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Yahoo! is not an investment adviser and does not provide, endorse or review any information or data contained herein....
Click here to read the whole Article (external link)